The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia.
Healthcare costs continue to rise with hospitalization representing the single largest component of direct medical costs associated with cancer care. Neutropenia and its complications including febrile neutropenia remain the major dose-limiting toxicity associated with systemic cancer chemotherapy. Febrile neutropenia often occurs early in the course of chemotherapy and is associated with substantial morbidity, mortality and cost. The colony-stimulating factors (CSFs) have been used effectively in a variety of clinical settings to prevent or treat febrile neutropenia and to assist patients receiving dose-intensive chemotherapy. A meta-analysis of the available randomized controlled trials (RCTs) has confirmed the efficacy of prophylactic CSFs. Economic models based on measures of resource utilization derived from RCTs have provided estimates of expected treatment costs along with febrile neutropenia risk threshold estimates for the cost saving use of the CSFs. Recent studies have demonstrated the potential value of targeting the CSFs toward patients at greatest risk based on accurate and valid predictive models.
Lyman
G H
GH
Department of Medicine, James P Wilmot Cancer Center, University of Rochester Medical Center, University of Rochester, Rochester, NY 14642, USA. gary_lyman@urmc.rochester.edu
Kuderer
N M
NM
D003115:Colony-Stimulating Factors / Q000191:economics* / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy* / Q000191:economics / Q000517:prevention & control*; D011788:Quality of Life; D015996:Survival Rate
D003115:Colony-Stimulating Factors